Lumosa Therapeutics and CHI Memorial announce new study for acute stroke
- Written by PR Newswire
TAIPEI and CHATTANOOGA, Tenn., Feb. 2, 2024 /PRNewswire/ -- Lumosa Therapeutics (Lumosa; 6535.TWO), together with CHI Memorial have announced the initiation of a Phase 2b clinical trial for LT3001, a groundbreaking drug for treating acute stroke. This new drug combines clot-busting and nerve-protecting effects into one treatment, potentially...
Read more: Lumosa Therapeutics and CHI Memorial announce new study for acute stroke














